



PanGenomic Health to Launch E-Commerce Platform for Personalized Natural Health

/NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, BC, Jan. 9, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it plans to launch its e-commerce platform for personalized natural health solutions this month. Built as an extension to its Nara consumer app and website launched in 2022, the e-commerce platform on nara.care will market its proprietary natural herbal remedy information library and practitioner-vetted brands. At launch, the Company plans to market its offering online in North America, with expansion into the UK and Europe subsequently this year.

"Finding the right natural remedy treatment for various health conditions has its challenges, given the uniqueness of each individual and the overwhelming amount of information out there", said Maryam Marissen, President & CEO of PanGenomic Health. "One of our first online products will be our Nara DNA Mind Report that assesses differences in people's genes and how they can impact the effectiveness of natural remedies when it comes to symptoms of underlying mental health conditions. We believe insights like these will greatly help consumers make more informed decisions when considering alternative natural therapeutic options."

The Company also announces that it is now trading on the Frankfurt Stock Exchange ("FSE") under the symbol "LL30". The Company's shares continue to be listed on the Canadian Securities Exchange under the symbol "NARA".

The FSE is one of the world's largest trading centres for securities and the largest stock exchange in Germany. Operated by the Deutsche Boerse AG, the FSE facilitates advanced electronic trading, settlement and information systems enabling it to meet the growing requirements of cross-border trading. The FSE is considered an international trading centre for investors.

About PanGenomic Health


PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because

PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedar.com.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE PanGenomic Health Inc.

 View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/January2023/09/c8911.html>

%SEDAR: 00039388E

For further information: Jerry Lai, Investor Relations, PanGenomic Health Inc., ir@pangenomic.com; Maryam Marissen, President & CEO, PanGenomic Health Inc., 778 743 4642, info@pangenomic.com

CO: PanGenomic Health Inc.

CNW 07:30e 09-JAN-23